Holen Sie sich die Stockscreener-App
9.01
2.06%
-0.21
Handel nachbörslich:
9.07
0.06
+0.67%
Alvotech Aktie (ALVO) Neueste Nachrichten
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar of Merck’s Keytruda for Global Cancer Treatment - geneonline.com
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Cancer Drug Pembrolizumab - geneonline.com
Short Interest in Alvotech (NASDAQ:ALVO) Grows By 75.2% - MarketBeat
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan - Center for Biosimilars
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Keytruda Cancer Drug - geneonline.com
Alvotech, Dr. Reddy’s to co-develop Keytruda biosimilar - Drug Store News
Alvotech (NASDAQ:ALVO) Shares Down 3.3%What's Next? - MarketBeat
Dr. Reddy’s shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar - MSN
Millennium Management LLC Trims Position in Alvotech (NASDAQ:ALVO) - MarketBeat
Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Merck's Keytruda - MSN
Linklaters Advises Syndicate on Alvotech’s SEK 750 Million Private Placement - Global Legal Chronicle
Alvotech Completes Private Placement to Boost Shareholder Base - TipRanks
Alvotech and Dr. Reddy’s Partner to Develop Biosimilar for Pembrolizumab Used in Cancer Treatment - geneonline.com
Alvotech completes private placement with 40 institutional investors By Investing.com - Investing.com Australia
Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors - The Manila Times
Alvotech Completes Successful Private Placement with Global Institutional Investors - Nasdaq
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - Yahoo Finance
REG-Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors - TradingView
Alvotech Attracts 40 New Global Investors in Strategic Private Placement, 80% First-Time Buyers - Stock Titan
Alvotech at Goldman Sachs Conference: Strategic Growth in Biosimilars - Investing.com
Alvotech at Goldman Sachs Conference: Strategic Growth in Biosimilars By Investing.com - Investing.com South Africa
Transcript : Alvotech Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 08 - marketscreener.com
Alvotech Partners with Dr. Reddy’s for Keytruda Biosimilar Development - TipRanks
Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet - MSN
Alvotech, Advanz Pharma expand biosimilar deal in Europe - Drug Store News
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment - MSN
Dr Reddy’s–Alvotech deal: Why investors are bullish - MSN
Dr Reddys Lab gains on global biosimilar deal with Alvotech - MSN
Alvotech (NASDAQ:ALVO) Stock Price Down 4.8%What's Next? - MarketBeat
Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab) - BioSpectrum Asia
Alvotech and Dr. Reddy’s Join Forces to Develop Biosimilar | - Chemical Industry Digest
Alvotech (ALVO) Partners with Dr. Reddy's for Keytruda Biosimila - GuruFocus
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda - MSN
Alvotech and Dr. Reddy’s partner for Keytruda biosimilar - Pharmaceutical Business review -
Dr Reddy's, Alvotech Partner To Develop Biosimilar For Cancer Treatment - MSN
Alvotech and Dr. Reddy’s to co-develop biosimilar to Keytruda - World Pharmaceutical Frontiers
Dr Reddy’s shares climb over 4% after Keytruda biosimilar deal with Alvotech - MSN
Alvotech to Participate in Goldman Sachs 46th Global Healthcare Conference in Miami - Nasdaq
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami - Yahoo
Alvotech (ALVO) Trading Down 4.8% on Jun 4 - GuruFocus
Alvotech Completes SEK 750 Million Private Placement to Boost R&D and Market Position - TipRanks
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga
Alvotech (ALVO) Trading Down 4.34% on Jun 5 - GuruFocus
2.13%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):